Table II.
Changes in quality of life outcomes reported by patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks
| Change from baseline | Week 12 Mean (SD) | Week 24 Mean (SD) | Week 52 Mean (SD) |
|---|---|---|---|
| EQ-5D-5L UK Index Score | |||
| UST | 0.1237 (0.217) | 0.1190 (0.212) | 0.1258 (0.221) |
| IXE | 0.1682 (0.226) | 0.1612 (0.228) | 0.1599 (0.242) |
| EQ-PsO Index Score | |||
| UST | 0.1173 (0.160) | 0.1210 (0.152) | 0.1204 (0.159) |
| IXE | 0.1512 (0.165)* | 0.1561 (0.159)* | 0.1421 (0.177) |
| EQ-5D VAS | |||
| UST | 10.10 (22.7) | 10.72 (22.7) | 12.52 (22.1) |
| IXE | 13.56 (22.3) | 15.38 (22.4) | 13.38 (22.5) |
*
p < 0.05 vs UST by Wilcoxon rank sum test.
SD: standard deviation; EQ-5D-5L: European Quality of Life – 5 Dimensions – 5 Level; EQ-PsO: European Quality of Life for Psoriasis; VAS: visual analogue scale.